Aoki H, Tani T, Hanasawa K, Shoji H, Kodama M
First Department of Surgery, Shiga University of Medical Science, Otsu, Japan.
Nihon Geka Gakkai Zasshi. 1993 Aug;94(8):775-80.
To remove endotoxin directly from the blood, an affinity adsorbent (PMX) has been developed. PMX is composed of a ligand of polymyxin B and a carrier of polystyrene fibers. We treated 16 patients, suffering from septic shock or multiple organ failure by PMX-F hemoperfusion. The pretreatment level of endotoxin decreased significantly from 80pg/ml to 21pg/ml on average 2 hours after the hemoperfusion. The hyperdynamic status in the cardiac index and the decreased systemic vascular resistance, which are characteristic to endotoxin shock, were normalized after the treatment. In septic shock patients with systolic pressure under 10mmHg, the systolic pressure increased significantly from pretreatment level. Nine of the sixteen patients remained alive for two weeks after the therapy, and seven out of the nine patients discharged alive. Hemoperfusion with PMX is likely to become an effective treatment for sepsis and septic shock.
为了直接从血液中去除内毒素,已开发出一种亲和吸附剂(PMX)。PMX由多粘菌素B配体和聚苯乙烯纤维载体组成。我们对16例患有脓毒性休克或多器官功能衰竭的患者进行了PMX-F血液灌流治疗。血液灌流平均2小时后,内毒素的预处理水平从80pg/ml显著降至21pg/ml。内毒素休克的特征性表现,即心脏指数的高动力状态和全身血管阻力的降低,在治疗后恢复正常。在收缩压低于10mmHg的脓毒性休克患者中,收缩压较预处理水平显著升高。16例患者中有9例在治疗后存活了两周,其中9例中有7例存活出院。PMX血液灌流可能会成为治疗脓毒症和脓毒性休克的有效方法。